Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.

被引：0
|
作者：
Motzer, Robert J.
Escudier, Bernard
Burotto, Mauricio
Powles, Thomas
Apolo, Andrea B.
Bourlon, Maria T.
Shah, Amishi Yogesh
Porta, Camillo
Suarez, Cristina
Barrios, Carlos H.
Richardet, Martin Eduardo
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
Rangwala, Fatima A.
Askelson, Margarita
Panzica, Julie
Fedorov, Viktor
Choueiri, Toni K.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Gustave Roussy, Villejuif, France
[3] Bradford Hill Clin Res Ctr, Santiago, Chile
[4] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, Royal Free Natl Hlth Serv Trust, London, England
[5] NCI, Ctr Canc Res, NIH, Bethesda, MD USA
[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Urol Oncol Clin, Mexico City, DF, Mexico
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[8] Univ Bari Aldo Moro, Bari, Italy
[9] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[10] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil
[11] Oncoclin Grp, Porto Alegre, Brazil
[12] Fdn Richardet Longo, Inst Oncol Cordoba, Cordoba, Argentina
[13] Westmead Hosp, Westmead, NSW, Australia
[14] Macquarie Univ, Westmead, NSW, Australia
[15] Westmead Hosp, Sydney, NSW, Australia
[16] Macquarie Univ, Sydney, NSW, Australia
[17] Univ Colorado, Sch Med, Aurora, CO USA
[18] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[19] Eva Mayr Stihl Canc Ctr, Klinikum Stuttgart, Stuttgart, Germany
[20] Exelixis Inc, Alameda, CA USA
[21] Bristol Myers Squibb, Princeton, NJ USA
[22] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[23] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.439
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial
    Bourlon, Maria Teresa
    Escudier, Bernard
    Burotto, Mauricio
    Powles, Thomas
    Apolo, Andrea B.
    Shah, Amishi Yogesh
    Porta, Camillo
    Suarez, Cristina
    Barrios, Carlos H.
    Richardet, Martin
    Gurney, Howard
    Kessler, Elizabeth R.
    Tomita, Yoshihiko
    Bedke, Jens
    Wang, Fong
    Wang, Peter
    Panzica, Julie
    Fedorov, Viktor
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 362 - 362
  • [2] Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for advanced renal cell carcinoma (aRCC): outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial
    Bedke, J.
    Powles, T.
    Burotto, M.
    Bourlon, M. T.
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Porta, C.
    Barrios, C.
    Gurney, H.
    Kessler, E. R.
    Retz, M.
    George, S.
    Escudier, B.
    Zhang, J.
    Simsek, B.
    Scheffold, C.
    Motzer, R. J.
    Choueiri, T. K.
    Apolo, A. B.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 24 - 25
  • [3] Nivolumab plus cabozantinib (N plus C) vs sunitinib for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial
    Pook, David
    Powles, Thomas
    Burotto, Mauricio
    Bourlon, Maria T.
    Hsieh, James J.
    Basso, Umberto
    Shah, Amishi Y.
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos
    Gurney, Howard
    Kessler, Elizabeth R.
    Retz, Margitta
    George, Saby
    Escudier, Bernard
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    Apolo, Andrea B.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 131 - 131
  • [4] Nivolumab plus cabozantinib (N plus C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.
    Apolo, Andrea B.
    Powles, Thomas
    Burotto, Mauricio
    Bourlon, Maria Teresa
    Hsieh, James J.
    Basso, Umberto
    Shah, Amishi Yogesh
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos H.
    Gurney, Howard
    Kessler, Elizabeth R.
    Retz, Margitta
    George, Saby
    Escudier, Bernard
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.
    Burotto, Mauricio
    Powles, Thomas
    Escudier, Bernard
    Apolo, Andrea B.
    Bourlon, Maria Teresa
    Shah, Amishi Yogesh
    Suarez, Cristina
    Porta, Camillo
    Barrios, Carlos H.
    Richardet, Martin
    Gurney, Howard
    Kessler, Elizabeth R.
    Tomita, Yoshihiko
    Bedke, Jens
    George, Saby
    Scheffold, Christian
    Wang, Peter
    Fedorov, Viktor
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [6] Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Motzer, Robert J.
    Powles, Thomas
    Burotto, Mauricio
    Apolo, Andrea B.
    Escudier, Bernard
    McDermott, David F.
    Braun, David A.
    Han, Celine
    Lee, George
    Dwivedi, Bhakti
    Li, Jun
    Gupta, Saurabh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Long-term follow-up results of nivolumab plus cabozantinib versus sunitinib for advanced renal cell cancer: Checkmate 9ER trial
    Tarigopula, Vivek
    INDIAN JOURNAL OF UROLOGY, 2022, 38 (04) : 317 - 318
  • [8] Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Burotto, Mauricio
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2022, 177 : 63 - 71
  • [9] Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N plus C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).
    Shah, Amishi Yogesh
    Motzer, Robert J.
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Zhang, Joshua
    Scheffold, Christian
    Karumanchi, Sravan
    Linh Thuy Nguyen
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] First-line nivolumab plus cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
    Porta, C. G.
    Burotto, M.
    Suarez Rodriguez, C.
    Bourlon, M. T.
    Hsieh, J.
    Shah, A. Y.
    Hamzaj, A.
    Bedke, J.
    Pook, D.
    Kessler, R.
    Tomita, Y.
    Drakaki, A.
    Zhang, J.
    Simsek, B.
    Schwab, G.
    Escudier, B.
    Motzer, R. J.
    Choueiri, T. K.
    Apolo, A. B.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S688 - S689
12345